AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
IMC-BEC2 cancer vaccine trial did not meet primary endpoint.
2004 JUL 7 - (NewsRx.com & NewsRx.net) -- ImClone Systems, Inc., (IMCL) and Merck, KGaA, of Darmstadt, Germany (MRK), announced that the international, randomized, phase III, clinical trial of the companies' IMC-BEC2 cancer vaccine did not meet its primary endpoint of survival.
IMC-BEC2 is an investigational anti-idiotypic monoclonal antibody that mimics GD3, a ganglioside expressed on the cell membrane of most small cell lung cancer tumors. The study was conducted in collaboration with the cooperative group European Organisation for Research and Treatment of Cancer (EORTC). The results of the clinical trial were presented by EORTC Investigator Giuseppe Giaccone, MD, PhD, department of oncology, Free University Medical Center, Amsterdam, the Netherlands, in a presentation at the American Society of Clinical Oncology annual meeting.
The clinical trial was designed to assess the survival benefit of vaccination with IMC-BEC2 and the immune stimulant BCG over a 2-year period. Patients in the trial were randomized into either the treatment ...
- ImClone Systems Incorporated Adopts Stockholder Rights Plan.
- Press release article from: Business Wire February 15, 2002 700+ words
...BW HealthWire)--Feb. 15, 2002 ImClone Systems Incorporated (NASDAQ: IMCL) announced...unsolicited attempts to acquire control of ImClone Systems which do not offer an adequate price...otherwise not in the best interests of ImClone Systems and its stockholders. ImClone ...
- ImClone Systems Reports First Quarter 2000 Financial Results.
- Press release article from: Business Wire May 16, 2000 700+ words
...BW HealthWire)--May 16, 2000 ImClone Systems Incorporated (Nasdaq:IMCL) announced...Quarterly Overview In January, ImClone Systems announced the issuance of a U.S...specific manner, RCR was developed by ImClone Systems and licensed to Abbott Laboratories...
- ImClone Systems and Bristol-Myers Squibb Enter Into Landmark Commercialization...
- Press release article from: Business Wire September 19, 2001 700+ words
...Acquire an Approximate 20 Percent Equity Stake in ImClone Systems ImClone Systems Incorporated (NASDAQ: IMCL) announced today...Food and Drug Administration (FDA) granted ImClone Systems a Fast Track designation for IMC-C225 in...
- ImClone Systems and Bristol-Myers Squibb Announce Revised Terms of...
- Press release article from: Business Wire March 5, 2002 700+ words
...Squibb Company (NYSE:BMY) and ImClone Systems Incorporated (Nasdaq: IMCL) announced...Bristol-Myers Squibb will pay ImClone Systems $140 million in cash upon signing...Bristol-Myers Squibb will pay ImClone Systems the originally agreed upon $500 million...
- ImClone Systems Announces Executive Changes.
- Press release article from: Business Wire May 22, 2002 700+ words
...BUSINESS WIRE)--May 22, 2002 ImClone Systems Incorporated (NASDAQ:IMCL) Samuel...Shareholders Adjourned Until June 11, 2002 ImClone Systems Incorporated (NASDAQ:IMCL), today...President and Chief Operating Officer of ImClone Systems, will succeed him in the positions...
- ImClone Systems Incorporated Announces Resignation of Harlan W. Waksal, M.D.,...
- Press release article from: Business Wire July 21, 2003 700+ words
...BUSINESS WIRE)--July 21, 2003 ImClone Systems Incorporated (NASDAQ: IMCL) announced...D., Chief Scientific Officer of ImClone Systems, has resigned from the Company effective...from his position as a Director of ImClone Systems' Board effective July 22, 2003...
- ImClone Systems Announces Erik D. Ramanathan Succeeds Clifford R. Saffron as...
- Press release article from: Business Wire September 22, 2004 700+ words
NEW YORK -- ImClone Systems Incorporated (NASDAQ: IMCL...Saffron as General Counsel of ImClone Systems. Mr. Saffron has resigned from...2005, after which he will leave ImClone Systems to pursue other interests. Mr...
- ImClone Systems Board of Directors Names Daniel S. Lynch Chief Executive...
- Press release article from: Business Wire February 12, 2004 700+ words
...BUSINESS WIRE)--Feb. 12, 2004 ImClone Systems Incorporated (NASDAQ: IMCL) announced...April 2003, Mr. Lynch has served as ImClone Systems' Senior Vice President, Chief Administrative...Board's decision was unanimous. ImClone Systems also announced today that David M...
Source: HighBeam Research, IMC-BEC2 cancer vaccine trial did not meet primary endpoint.